United States Biopharmaceuticals Contract Manufacturing Market to Grow with a CAGR of 10.72% through 2030
Technological
advancements in manufacturing processes and growing investments in biosimilar
production, is expected to drive the United States Biopharmaceuticals
Contract Manufacturing Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “United States Biopharmaceuticals Contract
Manufacturing Market – By Region and Competition, Forecast & Opportunities,
2030F”, the United States Biopharmaceuticals Contract Manufacturing Market was
valued at USD 10.58 Billion
in 2024 and is expected to reach USD 19.52 Billion by 2030 with a CAGR
of 10.72%. The United States biopharmaceuticals
contract manufacturing market is experiencing sustained expansion due to the
pharmaceutical industry's evolving business models and increasing complexity in
drug development. Biotech startups and mid-sized firms with limited
infrastructure are turning to contract manufacturing organizations (CMOs) to
support early-stage development and clinical trial production. The rising
prevalence of chronic and rare diseases is fueling demand for novel therapies
that require advanced production platforms. This shift is positioning CMOs as
essential partners in accelerating time-to-market, especially for companies
aiming to focus internal resources on innovation and pipeline development.
One
of the defining trends in the market is the integration of modular and agile
manufacturing strategies to meet fluctuating client demands. Contract
manufacturers are embracing platform-based approaches for monoclonal
antibodies, recombinant proteins, and viral vectors to increase production
agility. There is a growing preference for strategic partnerships, where CMOs
not only offer production capabilities but also contribute to process
development and regulatory filing support. The rise of decentralized clinical
trials and fast-track drug approvals is prompting manufacturers to ensure
supply chain responsiveness and reduce lead times, while still maintaining
product consistency and quality.
The
market presents significant growth opportunities in the area of cell and gene
therapy (CGT) manufacturing, which demands highly specialized and controlled
production environments. Increasing regulatory support for advanced therapy
medicinal products (ATMPs) and greater venture capital funding into biotech
firms are creating momentum for CMOs with capabilities in viral vector
production, cryopreservation, and fill-finish services tailored to CGT
pipelines. Expansion into niche services such as process intensification, tech
transfer, and integrated analytical testing is also opening new revenue
streams. As the focus on precision medicine grows, CMOs that can offer adaptive
capacity, regulatory expertise, and rapid development cycles are
well-positioned to capture an expanding share of outsourced biopharmaceutical
manufacturing demand.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "United States Biopharmaceuticals Contract Manufacturing Market”
The United
States Biopharmaceuticals Contract Manufacturing Market is segmented into source,
service, product, therapeutic area, regional distribution, and company.
Based on the Therapeutic
Area, Autoimmune Diseases emerged as the fastest growing segment in the United
States Biopharmaceuticals Contract Manufacturing Market during the forecast
period. This is due to the increasing prevalence of autoimmune disorders such
as rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel
disease, which collectively affect millions of patients across the country. The
complexity of these diseases requires advanced biologic therapies, including
monoclonal antibodies and targeted proteins, which have proven highly effective
in modulating the immune system and managing symptoms. Pharmaceutical companies
are investing heavily in developing innovative biologics tailored to treat
autoimmune conditions, which in turn fuels demand for specialized contract
manufacturing services. CMOs with expertise in producing these complex
molecules offer scalable solutions that accelerate development timelines and
ensure compliance with stringent regulatory standards. Additionally, the
growing emphasis on personalized medicine and targeted therapies is pushing the
need for flexible manufacturing processes capable of handling small to
mid-scale batches.
Based
on the Region, West emerged as the fastest growing region in the United
States Biopharmaceuticals Contract Manufacturing Market during the forecast period. This growth
is largely driven by the region’s robust biotechnology ecosystem, centered
around innovation hubs like California’s San Francisco Bay Area and San Diego.
The presence of numerous biotech startups, research institutions, and large
pharmaceutical companies fosters a strong demand for contract manufacturing
services, particularly for cutting-edge biologics and advanced therapies. The
West benefits from significant investment in research and development, enabling
rapid adoption of novel manufacturing technologies such as continuous
processing, single-use systems, and cell and gene therapy production.
Additionally, the region’s emphasis on sustainability and advanced
manufacturing practices attracts contract manufacturers aiming to implement
greener and more efficient production methods.
Major
companies operating in United States Biopharmaceuticals Contract Manufacturing
Market are:
- Lonza
Group Ltd.
- WuXi
Biologics Co., Ltd.
- Boehringer
Ingelheim International GmbH
- Thermo
Fisher Scientific Inc.
- Rentschler
Biopharma SE
- JRS
PHARMA GmbH & Co. KG
- AGC
Biologics
- ProBioGen
AG
- Samsung
Biologics
- FUJIFILM
Diosynth Biotechnologies
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The United States Biopharmaceuticals
Contract Manufacturing Market is expanding due to the accelerating shift of
biopharmaceutical companies toward outsourcing complex manufacturing processes
to specialized contract manufacturers. This trend is driven by the growing need
to reduce capital expenditure, optimize operational efficiency, and leverage
cutting-edge technologies that many in-house facilities lack. As biologics and
advanced therapies become more prevalent, companies increasingly rely on CMOs
to navigate stringent regulatory requirements and scale production rapidly
while maintaining high-quality standards. This collaborative approach allows
innovators to focus on research and development while ensuring robust,
flexible, and compliant manufacturing capabilities. Such strategic outsourcing
is anticipated to fuel sustained growth and innovation within the market.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“United States
Biopharmaceuticals Contract Manufacturing Market By Source (Mammalian,
Non-mammalian), By Service (Process Development, Fill & Finish Operations,
Analytical & QC studies, Packaging & Labelling, Others), By Product
(Biologics, Biosimilars), By Therapeutic Area (Oncology, Autoimmune Diseases,
Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Neurology,
Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”,
has evaluated the future growth potential of United States Biopharmaceuticals
Contract Manufacturing Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in United States Biopharmaceuticals
Contract Manufacturing Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com